Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China.
The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol during ventilation2–7.
Hospitals around the world have been using Aerogen’s closed-circuit nebuliser technology to deliver aerosolised medication to critically ill ventilated COVID-19 patients, with over 3 million patients being treated with Aerogen in 20208.
The company formed a Covid response unit in March 2020 to support projects researching potential treatments and vaccines and is now working with global pharmaceutical companies on the safe delivery of inhaled therapies. Aerogen’s technology is being used in several clinical trials8. Details of the most recent trial being published this week in the Lancet.
Aerogen’s innovative aerosol drug delivery technology was used in a Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) to adults without COVID-19 in China9. The Aerogen Ultra device was adapted to facilitate the study9.
The study concluded that the aerosol inhalation of Ad5-nCoV is painless, simple, well tolerated, and immunogenic, and the current data supports the evaluation of aerosolised Ad5-nCoV in ongoing phase 2 and 3 clinical trials9. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies9.
